Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Fresenius Medical Care

Fresenius Medical Care Raises $35B in Public

920 Winter Street, Waltham, MA 02451January 1, 20242 min read
Employees
130000+

Fresenius Medical Care Raises $35B in Public


Fresenius Medical Care has successfully raised $35B in a Public at a $38B valuation led by Public.


Company Overview


Fresenius Medical Care is a Healthcare company headquartered in 920 Winter Street, Waltham, MA 02451, founded in 1996 with 130000+ employees.


Dialysis products and services


Fundraising Details


  • Amount Raised: $35B
  • Round Type: Public
  • Valuation: $38B
  • Date: 2024-01-01
  • Investors: Public

About Fresenius Medical Care


Dialysis products and services The company is positioned in the Healthcare sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 920 Winter Street, Waltham, MA 02451
  • Founded: 1996
  • Team Size: 130000+
  • Industry: Healthcare

What This Means


This funding round demonstrates strong investor confidence in Fresenius Medical Care's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Healthcare sector continues to attract significant investment as companies innovate to meet evolving market demands. Fresenius Medical Care's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $38B valuation marks an important milestone for Fresenius Medical Care, positioning the company among notable players in the Healthcare industry.


Looking Ahead


With this new capital, Fresenius Medical Care is well-positioned to execute on its growth strategy and continue building innovative solutions in the Healthcare space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Fresenius Medical Care, visit their headquarters at 920 Winter Street, Waltham, MA 02451.

Company Info

Headquarters
920 Winter Street, Waltham, MA 02451
Founded
1996
Team Size
130000+

Topics

Fundraising(2912)Public(771)HealthcareFresenius Medical Care

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free